Vaxcell-Bio Therapeutics (323990) Fundamentals 2026 — Revenue Analysis | SniperIQ
Vaxcell-Bio Therapeutics (323990) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩89.5B, trading at ₩3860.00 on the KOE. This SniperIQ fundamentals page covers Vaxcell-Bio Therapeutics's valuation, profitability (net margin -213.8%), revenue (₩7.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Vaxcell-Bio Therapeutics's market cap?
Vaxcell-Bio Therapeutics (323990) has a market capitalization of approximately ₩89.5B, trading at ₩3860.00 on the KOE. Market cap moves with the live share price.
What is Vaxcell-Bio Therapeutics's P/E ratio?
Vaxcell-Bio Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Vaxcell-Bio Therapeutics?
Vaxcell-Bio Therapeutics runs a net profit margin of -213.8%, a gross margin of -3.8%, and an operating margin of -231.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Vaxcell-Bio Therapeutics generate?
Vaxcell-Bio Therapeutics reported revenue of ₩7.1B for fiscal year 2025, with net income of -₩13.3B and earnings per share (EPS) of -577.4. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Vaxcell-Bio Therapeutics pay a dividend?
Vaxcell-Bio Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Vaxcell-Bio Therapeutics financially healthy?
Vaxcell-Bio Therapeutics carries a debt-to-equity ratio of 0.03x and a current ratio of 6.15x, with a market beta of 0.40. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Vaxcell-Bio Therapeutics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Vaxcell-Bio Therapeutics (323990) the key facts are: market cap ₩89.5B, revenue ₩7.1B, 52-week range 3815-11520. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Vaxcell-Bio Therapeutics's full fundamentals live
Get Vaxcell-Bio Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.